EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Repulsive Guidance Molecule-A as a Therapeutic Target Across Neurological Disorders: An Update

Vasilis-Spyridon Tseriotis iD, Andreas Liampas iD, Irene Zacharo Lazaridou iD, Sofia Karachrysafi iD, George D Vavougios, Georgios M Hadjigeorgiou iD, Theodora Papamitsou iD, Dimitrios Kouvelas, Marianthi Arnaoutoglou, Chryssa Pourzitaki iD, Theodoros Mavridis iD

International Journal of Molecular Sciences · 30.03.2025 · 26 (7) · 3221

DOI: 10.3390/ijms26073221 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.03.2025. Verfasst von Vasilis-Spyridon Tseriotis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Agios Pavlos General Hospital of Thessaloniki, 55134 Thessaloniki, Greece. Hauptthemen laut MEDLINE: Nervous System Diseases, Nerve Tissue Proteins, GPI-Linked Proteins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Repulsive guidance molecule-a (RGMa) has emerged as a significant therapeutic target in a variety of neurological disorders, including neurodegenerative diseases and acute conditions. This review comprehensively examines the multifaceted role of RGMa in central nervous system (CNS) pathologies such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis, neuromyelitis optica spectrum disorder, spinal cord injury, stroke, vascular dementia, auditory neuropathy, and epilepsy. The mechanisms through which RGMa contributes to neuroinflammation, neuronal degeneration, and impaired axonal regeneration are herein discussed. Evidence from preclinical studies associate RGMa overexpression with negative outcomes, such as increased neuroinflammation and synaptic loss, while RGMa inhibition, particularly the use of agents like elezanumab, has shown promise in enhancing neuronal survival and functional recovery. RGMa’s responses concerning immunomodulation and neurogenesis highlight its potential as a therapeutic avenue. We emphasize RGMa’s critical role in CNS pathology and its potential to pave the way for innovative treatment strategies in neurological disorders. While preclinical findings are encouraging so far, further clinical trials are needed to validate the safety and efficacy of RGMa-targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nervous System DiseasesNerve Tissue ProteinsGPI-Linked ProteinsHumansAnimalsMolecular Targeted TherapyNeurodegenerative Diseases

Stichwörter der Autor:innen

amyotrophic lateral sclerosisauditory neuropathyepilepsymultiple sclerosisneuromyelitis optica spectrum disorderrepulsive guidance molecule-aspinal cord injurystroke

Substanzen

Nerve Tissue ProteinsGPI-Linked ProteinsRGMA protein, human

Autor:innen und Institutionen

  • Department of Neurology, Agios Pavlos General Hospital of Thessaloniki, 55134 Thessaloniki, Greece.
  • Laboratory of Clinical Pharmacology, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
  • Department of Neurology, Nicosia General Hospital, Strovolos, 2031 Nicosia, Cyprus.
  • Department of Neurology, Medical School, University of Cyprus, 1678 Nicosia, Cyprus.
  • Department of Neurology, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
  • Research Team "Histologistas", Interinstitutional Postgraduate Program "Health and Environmental Factors", Department of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Gr…

ORCID-Profile: Vasilis-Spyridon Tseriotis, Andreas Liampas, Irene Zacharo Lazaridou, Sofia Karachrysafi, Georgios M Hadjigeorgiou, Theodora Papamitsou, Chryssa Pourzitaki, Theodoros Mavridis

Zitieren

APA

Tseriotis, V. S., Liampas, A., Lazaridou, I. Z., Karachrysafi, S., Vavougios, G. D., Hadjigeorgiou, G. M., Papamitsou, T., Kouvelas, D., Arnaoutoglou, M., Pourzitaki, C., & Mavridis, T. (2025). Repulsive Guidance Molecule-A as a Therapeutic Target Across Neurological Disorders: An Update. International Journal of Molecular Sciences, 26(7), 3221. https://doi.org/10.3390/ijms26073221

Vancouver

Tseriotis VS, Liampas A, Lazaridou IZ, Karachrysafi S, Vavougios GD, Hadjigeorgiou GM, et al. Repulsive Guidance Molecule-A as a Therapeutic Target Across Neurological Disorders: An Update. International Journal of Molecular Sciences. 2025;26(7):3221. doi:10.3390/ijms26073221

BibTeX
@article{Tseriotis2025,
  author = {Tseriotis, Vasilis-Spyridon and Liampas, Andreas and Lazaridou, Irene Zacharo and Karachrysafi, Sofia and Vavougios, George D and Hadjigeorgiou, Georgios M and Papamitsou, Theodora and Kouvelas, Dimitrios and Arnaoutoglou, Marianthi and Pourzitaki, Chryssa and Mavridis, Theodoros},
  title = {Repulsive Guidance Molecule-A as a Therapeutic Target Across Neurological Disorders: An Update},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {7},
  pages = {3221},
  doi = {10.3390/ijms26073221}
}
Kostenlos starten →